Role of Recombinant Activated Factor VII in the Management of Life-threatening Coagulopathic Bleeding

Roberts H.R. , Monroe D.M. , Escobar M.A. Current concepts of hemostasis. Anesthesiology 2004; 100: 722–730.

Australian Government Department of Health and Aging Therapeutic Goods Administration Website: www.tga.gov.au

Eikelboom J.W. , Bird R. , Blythe D. Recombinant activated factor VII for the treatment of life-threatening haemorrhage. Blood Coag Fibrinol 2003; 14: 713–717.

Kenet G. , Walden R. , Elad A. , Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999; 354: 1879.

Martinowitz U. , Kenet G. , Segal E. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001; 51: 431–439.

Moscardo F. , Perez F. , de la Rubia J. . Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII. Br J Haematol 2001; 113: 174–176.

Friederich P.W. , Geerdink M.G.F. , Spatoro M. The effect of the administration of recombinant activated factor VII (NovoSeven() on perioperative blood loss in patients undergoing transabdominal retropubic prostatectomy: the PROSE study. Blood Coag Fibrin 2000; 11(Suppl 1): S129–S132.

Hendriks H.G. , van der Maaten , de Wolf J. An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII. Anesth Analg 2001; 93: 287–289.

Von Heymann C. , Hotz H. , Konertz W. , Kox W.J. , Spies C. Successful treatment of refractory bleeding with recombinant factor VIIa after redo coronary artery bypass graft surgery. J Cardiothor Vasc Anesth 2002; 16: 615–616.

Shami V.M. , Caldwell S.H. , Hespenheide E.E. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transplantation 2003; 9: 138–143.

Gowers C.J.D. , Parr M.J.A. Recombinant activated factor VIIa (rFVIIa) use in massive transfusion and coagulopathy unresponsive to conventional therapy. Anaesth Intensive Care 2005; 33: 196–200.

Gibbs N.M. Management of severe peri-operative coagu-lopathy: Role of recombinant activated factor VII. In Keneally J. , Jones M. (Eds). Australasian Anaesthesia 2003, Australian and New Zealand College of Anaesthetists, Melbourne, 2003, pp. 137–147.

Roberts H.R. , Monroe D.M. , Hoffman M. Safety profile of recombinant factor VIIa. Semin Hematol 2004; 41(Suppl 1): 101–108.

Erhardtsen E. Ongoing NovoSeven^® trials. Intensive Care Med 2002; 28: S248–S255.